CytoSorbents Corporation (NASDAQ: CTSO) was founded in 1997, formerly known as MedaSorb Technologies Corporation, and changed to its current name in May 2010. It is headquartered in Monmouth Junction, New Jersey, USA, with 153 full-time employees. It is an immunology company specializing in intensive care Therapeutics company, whose blood purification technology platform combines global proprietary adsorbent and porous polymer technology, is committed to the research, development and commercialization of medical devices .
CytoSorbents Corporation (CTSO):
CytoSorbents Corporation is a public company located in Monmouth Junction, New Jersey. CytoSorbents created a blood purification technology based on biocompatible porous polymer beads. This polymer bead acts like a sponge and aims to remove harmful substances from the blood. The company’s first product, CytoSorb, received CE mark approval in 2011.
Cytosorbents Corporation’s flagship product is CytoSorb, which is an in vitro cytokine filter designed for adjuvant treatment of sepsis; adjuvant treatment in other intensive care applications; prevention and treatment of complications after extracorporeal bypass surgery; prevention And to treat the organ dysfunction of brain-dead organ donors in order to increase the quantity and quality of surviving organs collected from donors.
Cytosorbents also provides VetResQ equipment for the auxiliary treatment of sepsis, pancreatitis and other serious animal diseases.
In addition, Cytosorbents Corporation has also developed the CytoSorb-XL device for the adjuvant treatment of sepsis and other serious diseases; the HemoDefend blood purification technology platform can reduce the contaminants in the blood supply, which are used in patients when blood and blood products are used. Can cause blood transfusion reactions or diseases; K+ontrol, a blood purification technology in the development stage; and ContrastSorb are used to remove IV contrast agents in the blood during CT imaging, angiography or vascular interventional radiology procedures to reduce The risk of contrast-induced kidney disease.
Furthermore, Cytosorbents Corporation is also engaged in the development of BetaSorb, a device used to prevent and treat health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood substance.
In 2014, CytoSorbents won a US$3.8 million contract awarded by the Defense Advanced Research Projects Agency (DARPA). The contract involves the “Dialysis-Like Therapeutics” program, which aims to treat sepsis by removing cytokines and pathogen toxins. The US Army awarded the company a $1.15 million small business innovation research contract to evaluate burn and trauma technology.